Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04XJM
|
|||
| Former ID |
DCL000013
|
|||
| Drug Name |
R1295
|
|||
| Synonyms |
CHEMBL2146615
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20] | Discontinued in Phase 1 | [1] | |
| Company |
Roche
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C9H10O3
|
|||
| Canonical SMILES |
CC1=CC=C(C=C1)OCC(=O)O
|
|||
| InChI |
1S/C9H10O3/c1-7-2-4-8(5-3-7)12-6-9(10)11/h2-5H,6H2,1H3,(H,10,11)
|
|||
| InChIKey |
SFTDDFBJWUWKMN-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 940-64-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Integrin alpha-4/beta-7 (ITGA4/B7) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. | |||
| REF 2 | Vedolizumab: an 47 integrin inhibitor for inflammatory bowel diseases.Ann Pharmacother.2014 Dec;48(12):1629-35. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.